A citation-based method for searching scientific literature


List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
582
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu, Christian Sonesson, Eva Johnsson. J Diabetes Complications 2017
24
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
527
25

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court,[...]. Health Technol Assess 2017
28
25

Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Naoto Terami, Daisuke Ogawa, Hiromi Tachibana, Takashi Hatanaka, Jun Wada, Atsuko Nakatsuka, Jun Eguchi, Chikage Sato Horiguchi, Naoko Nishii, Hiroshi Yamada,[...]. PLoS One 2014
175
25

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
199
25

Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.
N N Hamouda, V Sydorenko, M A Qureshi, J M Alkaabi, M Oz, F C Howarth. Mol Cell Biochem 2015
37
25


Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
L A Leiter, W T Cefalu, T W A de Bruin, J Xu, S Parikh, E Johnsson, I Gause-Nilsson. Diabetes Obes Metab 2016
16
25


Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press 2016
59
25

Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Frederik Persson, Thomas Nyström, Marit E Jørgensen, Bendix Carstensen, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W Eriksson, Anna Norhammar,[...]. Diabetes Obes Metab 2018
115
25

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.
Hector E Tamez, Alejandra L Tamez, Lucas A Garza, Mayra I Hernandez, Ana C Polanco. J Diabetes Metab Disord 2015
26
25

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Kayoko Ikehara, Eiichiro Kanda, Hiroshi Uchino, Takahisa Hirose. Cardiovasc Diabetol 2017
113
25

Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.
Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Panagiota Boura, Apostolos Tsapas. Ther Adv Endocrinol Metab 2015
22
25

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Sreeneeranj Kasichayanula, Xiaoni Liu, Frank Lacreta, Steven C Griffen, David W Boulton. Clin Pharmacokinet 2014
120
25

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.
Jagdeep S S Singh, Amir Fathi, Keeran Vickneson, Ify Mordi, Mohapradeep Mohan, J Graeme Houston, Ewan R Pearson, Allan D Struthers, Chim C Lang. Cardiovasc Diabetol 2016
39
25

A Review on the Relationship between SGLT2 Inhibitors and Cancer.
Hao-Wen Lin, Chin-Hsiao Tseng. Int J Endocrinol 2014
57
25

[Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Pol Sanz-Serra, Juan Pedro-Botet, Juana A Flores-Le Roux, David Benaiges, Juan J Chillarón. Clin Investig Arterioscler 2015
1
100


The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice.
Weiling Leng, Xinshou Ouyang, Xiaotian Lei, Mingxia Wu, Liu Chen, Qinan Wu, Wuquan Deng, Ziwen Liang. Mediators Inflamm 2016
71
25

Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.
Y Wang, L Xu, L Yuan, D Li, Y Zhang, R Zheng, C Liu, X Feng, Q Li, Q Li,[...]. Diabet Med 2016
15
25


Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
Christian Sonesson, Peter A Johansson, Eva Johnsson, Ingrid Gause-Nilsson. Cardiovasc Diabetol 2016
115
25

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
457
25


Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne-Rawson, Jennifer Newman,[...]. Cardiovasc Diabetol 2014
133
25

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
J Dziuba, P Alperin, J Racketa, U Iloeje, D Goswami, E Hardy, I Perlstein, H L Grossman, M Cohen. Diabetes Obes Metab 2014
65
25

All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
Konstantinos A Toulis, Brian H Willis, Tom Marshall, Balachadran Kumarendran, Krishna Gokhale, Sandip Ghosh, G Neil Thomas, Kar Keung Cheng, Parth Narendran, Wasim Hanif,[...]. J Clin Endocrinol Metab 2017
48
25


Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Sreeneeranj Kasichayanula, Ming Chang, Xiaoni Liu, Wen-Chyi Shyu, Steven C Griffen, Frank P LaCreta, David W Boulton. Adv Ther 2012
42
25


Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Feng-Fei Li, Gu Gao, Qian Li, Hong-Hong Zhu, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. J Diabetes Res 2016
15
25




2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.
Karen A Hicks, Kenneth W Mahaffey, Roxana Mehran, Steven E Nissen, Stephen D Wiviott, Billy Dunn, Scott D Solomon, John R Marler, John R Teerlink, Andrew Farb,[...]. Circulation 2018
148
25

Health-Related Quality of Life Outcomes in PARADIGM-HF.
Eldrin F Lewis, Brian L Claggett, John J V McMurray, Milton Packer, Martin P Lefkowitz, Jean L Rouleau, Jiankang Liu, Victor C Shi, Michael R Zile, Akshay S Desai,[...]. Circ Heart Fail 2017
89
25

Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. N Engl J Med 2014
25


Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.
B M Scirica, E Braunwald, I Raz, M A Cavender, D A Morrow, P Jarolim, J A Udell, O Mosenzon, K Im, A A Umez-Eronini,[...]. Circulation 2015
35
25


Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
Jennifer K Rogers, John J V McMurray, Stuart J Pocock, Faiez Zannad, Henry Krum, Dirk J van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Bertram Pitt. Circulation 2012
67
25


SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar, James McLaren, Søren L Kristensen, David Preiss, John J McMurray. Diabetologia 2016
177
25

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton. Diabetes Obes Metab 2018
182
25

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Ulrik M Mogensen, Jianjian Gong, Pardeep S Jhund, Li Shen, Lars Køber, Akshay S Desai, Martin P Lefkowitz, Milton Packer, Jean L Rouleau, Scott D Solomon,[...]. Eur J Heart Fail 2018
41
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.